Biogen/Elan Submit Applications For Tysabri Label Change Ahead of Schedule
This article was originally published in The Pink Sheet Daily
Executive Summary
In a bid to solidify Tysabri's place in an increasingly competitive market, Biogen/Elan push forward with changes to the multiple sclerosis medicine's label that help define the risk of a rare brain infection.